We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: GLP-1 receptor agonists
MedXY News
EnglishTag

GLP-1 receptor agonists

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Evaluating Complication Rates in Post-Weight-Loss Body Contouring: Comparing Surgery, GLP-1 Pharmacotherapy, Combination, and Lifestyle Approaches
Diabetes & Endocrinologyweight lossbariatric surgery

Evaluating Complication Rates in Post-Weight-Loss Body Contouring: Comparing Surgery, GLP-1 Pharmacotherapy, Combination, and Lifestyle Approaches

By MedXY|Sep 3, 2026

This study investigates postoperative complication rates following body-contouring surgery among patients with differing weight-loss methods, revealing that weight-loss modality does not affect complications, while BMI and diabetes at surge

Impact of Weight-Loss Methods on Post-Bariatric Body Contouring Surgery Outcomes: A Comparative Analysis
Diabetes & Endocrinology
bariatric surgery
GLP-1 receptor agonists

Impact of Weight-Loss Methods on Post-Bariatric Body Contouring Surgery Outcomes: A Comparative Analysis

By MedXY|Sep 2, 2026

This study examines complication rates following body-contouring surgeries in patients after weight loss via bariatric surgery, GLP-1 receptor agonists, combination therapy, or lifestyle changes, finding modality-independent risk but highli

Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness: A Comprehensive Review
CardiologyGLP-1 receptor agonistsserious mental illness

Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness: A Comprehensive Review

By MedXY|Sep 2, 2026

GLP-1 receptor agonists reduce mortality and cardiovascular events more effectively than SGLT2 inhibitors in serious mental illness (SMI), with early benefits and consistent effects across bipolar disorder, major depression, and schizophren

Impact of Weight-Loss Methods on Post-Bariatric Body Contouring Surgery Outcomes: A Comparative Analysis
Diabetes & Endocrinologyweight lossbariatric surgery

Impact of Weight-Loss Methods on Post-Bariatric Body Contouring Surgery Outcomes: A Comparative Analysis

By MedXY|Sep 1, 2026

This study evaluates complication rates following body contouring after weight loss via bariatric surgery, GLP-1 receptor agonists, combination therapy, and lifestyle changes, finding weight-loss modality does not affect postoperative compl

GLP1R R131Q Variant: A Genetic Key to Preserving β-Cell Function and Enhancing GLP-1RA Efficacy in Type 2 Diabetes
Diabetes & Endocrinologypharmacogeneticsβ-cell function

GLP1R R131Q Variant: A Genetic Key to Preserving β-Cell Function and Enhancing GLP-1RA Efficacy in Type 2 Diabetes

By MedXY|Aug 26, 2026

The gain-of-function GLP1R R131Q variant slows β-cell decline and improves glycemic response to GLP-1 receptor agonists, highlighting its potential role in precision diabetes therapeutics.

Exploring the Link Between GLP-1 Receptor Agonists and Sensory Disturbances in Diabetes Care
Diabetes & EndocrinologyGLP-1 receptor agonistsSmell disturbance

Exploring the Link Between GLP-1 Receptor Agonists and Sensory Disturbances in Diabetes Care

By MedXY|Aug 17, 2026

This study reveals a significant association between GLP-1 receptor agonist therapy and increased risk of smell and taste disturbances in type 2 diabetes patients, highlighting the need for awareness and monitoring.

GLP-1 Receptor Agonists May Reduce Hospital Admissions for Alcohol and Substance Use Disorders: Insights from a Swedish Nationwide Study
Diabetes & Endocrinologyhospitalisation ratesdiabetes

GLP-1 Receptor Agonists May Reduce Hospital Admissions for Alcohol and Substance Use Disorders: Insights from a Swedish Nationwide Study

By MedXY|Aug 10, 2026

This Swedish register-based study reveals that GLP-1 receptor agonists are associated with significantly reduced hospitalisations for alcohol and substance use disorders during treatment, with some lasting benefits after discontinuation of

Crowded Optic Discs and Risk Stratification of NAION in GLP-1 Receptor Agonist Users: Insights from a Large Multicenter Study
Diabetes & Endocrinologycup-to-disc ratioNAION

Crowded Optic Discs and Risk Stratification of NAION in GLP-1 Receptor Agonist Users: Insights from a Large Multicenter Study

By MedXY|Aug 10, 2026

This large multicenter study reveals that nonarteritic anterior ischemic optic neuropathy (NAION) patients exposed to GLP-1 receptor agonists exhibit similar optic disc crowding compared to nonexposed patients, with smaller cup-to-disc rati

Pooled Analysis of SELECT, FLOW, and SOUL Links Semaglutide to Reduced Kidney Outcomes
Diabetes & Endocrinologycardio-kidney-metabolic diseasesemaglutide

Pooled Analysis of SELECT, FLOW, and SOUL Links Semaglutide to Reduced Kidney Outcomes

By MedXY|Aug 8, 2026

A prespecified pooled analysis of three phase 3 trials including 30,787 participants found semaglutide reduced major kidney outcomes versus placebo, with a 16% relative risk reduction in the primary composite and a favourable safety profile across cardio-kidney-metabolic disease.

Evaluating the Risk of Anterior Ischemic Optic Neuropathy with GLP-1 Receptor Agonists in Type 2 Diabetes: Insights from a Swedish Nationwide Cohort Study
Diabetes & EndocrinologyGLP-1 receptor agoniststype 2 diabetes

Evaluating the Risk of Anterior Ischemic Optic Neuropathy with GLP-1 Receptor Agonists in Type 2 Diabetes: Insights from a Swedish Nationwide Cohort Study

By MedXY|Aug 5, 2026

A large Swedish cohort study assesses whether glucagon-like peptide-1 receptor agonists increase the risk of anterior ischemic optic neuropathy in type 2 diabetes. Although a borderline elevated relative risk was observed, absolute incidenc

Evaluating GLP-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes: Insights from a Veterans Health Administration Target Trial Emulation
Diabetes & Endocrinologycomparative effectivenessGLP-1 receptor agonists

Evaluating GLP-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes: Insights from a Veterans Health Administration Target Trial Emulation

By MedXY|Aug 4, 2026

A large study in veterans with type 2 diabetes found that adding GLP-1 receptor agonists to basal insulin did not improve insulin discontinuation rates compared to SGLT-2 inhibitors or DPP-4 inhibitors over three years.

GLP-1 Receptor Agonists: A Breakthrough in Reducing Atherosclerosis and Cardiovascular Risk Beyond Diabetes and Obesity
Cardiologyatherosclerosiscardiovascular events

GLP-1 Receptor Agonists: A Breakthrough in Reducing Atherosclerosis and Cardiovascular Risk Beyond Diabetes and Obesity

By MedXY|Jul 22, 2026

GLP-1 receptor agonists significantly reduce atherosclerosis progression, inflammatory biomarkers, and cardiovascular events independent of glycaemic control and obesity status, evidenced by robust preclinical and large-scale clinical data.

GLP-1 Receptor Agonists and the Risk of Ischemic Optic Neuropathy in Type 2 Diabetes: Evidence from a Target Trial Emulation
Diabetes & EndocrinologyGLP-1 receptor agonistsischemic optic neuropathy

GLP-1 Receptor Agonists and the Risk of Ischemic Optic Neuropathy in Type 2 Diabetes: Evidence from a Target Trial Emulation

By MedXY|Jul 17, 2026

This study evaluates the association between GLP-1 receptor agonists and ischemic optic neuropathy risk compared to SGLT2 and DPP-4 inhibitors, revealing a small but statistically significant increased risk with GLP-1RAs, particularly among

Harnessing Real-World Evidence to Optimize GLP-1-Based Therapies: Insights from a NIDDK Workshop
Diabetes & EndocrinologydiabetesGLP-1 receptor agonists

Harnessing Real-World Evidence to Optimize GLP-1-Based Therapies: Insights from a NIDDK Workshop

By MedXY|Jul 7, 2026

A NIDDK workshop highlighted the crucial role of real-world evidence in addressing gaps about GLP-1 receptor agonists’ safety, effectiveness, adherence, and economic impact to improve clinical and regulatory decision-making.

Glucagon-like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors Following Liver Resection for Hepatocellular Carcinoma in Type 2 Diabetes: Insights from a Target Trial Emulation Study
Clinical UpdatesDPP‑4 inhibitorsGLP-1 receptor agonists

Glucagon-like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors Following Liver Resection for Hepatocellular Carcinoma in Type 2 Diabetes: Insights from a Target Trial Emulation Study

By MedXY|Jul 5, 2026

Postoperative GLP-1RA initiation after liver resection for hepatocellular carcinoma in type 2 diabetes patients is associated with improved recurrence-free and overall survival compared to DPP-4 inhibitors, indicating potential incremental

GLP-1 Receptor Agonists May Outperform Bariatric Surgery for Breast Cancer Outcomes in Obese Postmenopausal Women
Diabetes & Endocrinologybariatric surgerybreast cancer

GLP-1 Receptor Agonists May Outperform Bariatric Surgery for Breast Cancer Outcomes in Obese Postmenopausal Women

By MedXY|Jun 19, 2026

In a large TriNetX study, GLP-1 receptor agonists were associated with better overall survival and lower locoregional recurrence than bariatric surgery alone in obese postmenopausal women with stage 0-III breast cancer.

GLP-1 Receptor Agonists May Outperform Bariatric Surgery in Obese Postmenopausal Breast Cancer Patients, Study Suggests
Hematology-Oncologybreast cancerobesity

GLP-1 Receptor Agonists May Outperform Bariatric Surgery in Obese Postmenopausal Breast Cancer Patients, Study Suggests

By MedXY|Aug 18, 2026

A large real-world study found GLP-1 receptor agonists were associated with better survival and lower locoregional recurrence than bariatric surgery in postmenopausal women with obesity and breast cancer.

Individual GLP-1 Receptor Agonists and SGLT2 Inhibitors Show Largely Comparable Cardiovascular Protection in Type 2 Diabetes
Cardiologycardiovascular outcomesGLP-1 receptor agonists

Individual GLP-1 Receptor Agonists and SGLT2 Inhibitors Show Largely Comparable Cardiovascular Protection in Type 2 Diabetes

By MedXY|Jun 10, 2026

A multinational real-world study found broadly similar cardiovascular effectiveness across individual GLP-1 receptor agonists and SGLT2 inhibitors in metformin-treated type 2 diabetes, including among patients with established cardiovascula

GLP-1 Weight-Loss and Diabetes Drugs: What Eye Specialists Say About NAION Risk
newsGLP-1 receptor agonistsNAION

GLP-1 Weight-Loss and Diabetes Drugs: What Eye Specialists Say About NAION Risk

By MedXY|May 18, 2026

A new consensus statement advises cautious, shared decision-making about GLP-1 receptor agonists and NAION risk, noting that current evidence is observational, conflicting, and suggests any absolute risk increase is small.

GLP-1 Receptor Agonists Show Lower Heart Failure Risk Versus DPP-4 Inhibitors in Type 2 Diabetes
CardiologyDPP‑4 inhibitorsGLP-1 receptor agonists

GLP-1 Receptor Agonists Show Lower Heart Failure Risk Versus DPP-4 Inhibitors in Type 2 Diabetes

By MedXY|May 2, 2026

New research comparing diabetes medications reveals GLP-1 receptor agonists lower heart failure hospitalization risk compared to DPP-4 inhibitors, while showing similar risk to SGLT-2 inhibitors in type 2 diabetes patients.

1 / 3
123
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities